Immune Checkpoint Inhibitors in Type 1 Diabetes: A New Frontier in Therapy

Article · March 2024

CITATIONS
0

READS
37

2 authors:

Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,422 PUBLICATIONS **11,224** CITATIONS
SEE PROFILE

Getrude Uzoma Obeagu
Kampala International University (KIU)
384 PUBLICATIONS **3,307** CITATIONS
SEE PROFILE

Elite Journal of Medicine. Volume 2 issue 2(2024), Pp. 26-41
https://epjournals.com/journals/EJM

Immune Checkpoint Inhibitors in Type 1 Diabetes: A New Frontier in Therapy

[*]Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

[2]School of Nursing Science, Kampala International University, Uganda,
uzomagertrude@gmail.com

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Type 1 Diabetes (T1D) is a chronic autoimmune disease characterized by the immune-mediated destruction of insulin-producing beta cells in the pancreas. Current therapeutic strategies primarily focus on glycemic control through exogenous insulin administration. However, emerging research has explored the potential of immune checkpoint inhibitors (ICIs), initially developed for cancer immunotherapy, as a novel therapeutic approach for T1D. This abstract provides a concise overview of the current landscape of ICIs in T1D therapy, highlighting their mechanisms of action, preclinical and clinical studies, challenges, and future prospects. ICIs target key immune checkpoint molecules, including CTLA-4, PD-1, and PD-L1, aiming to modulate immune responses. In T1D, these inhibitors hold the promise of reining in autoreactive T cells, thereby preserving beta cell function and slowing disease progression. Extensive preclinical investigations in murine models have demonstrated the efficacy of ICIs in preventing the autoimmune destruction of beta cells. These studies provide crucial insights into the mechanisms underlying T-cell regulation and offer a foundation for translating findings into clinical applications. In conclusion, immune checkpoint inhibitors represent a promising frontier in T1D therapy, offering a paradigm shift towards immune modulation for disease modification. This abstract provides a snapshot of the current status of ICIs in T1D research and underscores the need for ongoing investigations, precision medicine approaches, and collaborative efforts to unlock the full potential of these innovative therapies.

Citation: Obeagu EI, Obeagu GU. Immune Checkpoint Inhibitors in Type 1 Diabetes: A New Frontier in Therapy. Elite Journal of Medicine, 2024; 2(2): 26-41

Keywords: *Type 1 Diabetes, Immune Checkpoint Inhibitors, Autoimmunity, Immunotherapy, T-cell Regulation, Beta Cell Preservation, Precision Medicine*

Introduction

Type 1 Diabetes (T1D) is a chronic autoimmune disorder characterized by the selective destruction of insulin-producing beta cells in the pancreas, resulting in a lifelong dependence on exogenous insulin. Despite advancements in insulin therapy, the quest for disease-modifying treatments that address the underlying autoimmune pathology remains a pressing need.[1-4] In recent years, immune checkpoint inhibitors (ICIs), originally designed to unleash the immune system against cancer cells, have emerged as a novel and promising avenue for therapeutic intervention in T1D.[5] Traditionally, T1D has been managed by insulin replacement therapy to control hyperglycemia and prevent acute complications.[6] However, this approach does not address the root cause of the disease—the autoimmune assault on pancreatic beta cells. Immune checkpoint inhibitors (ICIs), known for their success in cancer immunotherapy, operate by releasing the brakes on immune responses, particularly by targeting key checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand PD-L1. This innovative strategy holds the potential to modulate aberrant immune responses, preserving beta cell function and slowing the progression of T1D.[7]

The aim of exploring immune checkpoint inhibitors (ICIs) in the context of Type 1 Diabetes (T1D) is to investigate novel therapeutic strategies that could potentially modify the course of the disease.

Mechanisms of Action

Immune checkpoint inhibitors (ICIs) represent a class of therapeutic agents designed to modulate the immune system by targeting specific checkpoint molecules involved in immune regulation.[8] In the context of Type 1 Diabetes (T1D), these agents hold the potential to disrupt the autoimmune attack on insulin-producing beta cells. Understanding the intricate mechanisms of action underlying ICIs provides insights into their application and potential efficacy in T1D therapy. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key inhibitory receptor expressed on T cells.[9] It competes with the co-stimulatory receptor CD28 for binding to B7 molecules on antigen-presenting cells. By inhibiting T cell activation and proliferation, CTLA-4 acts as a crucial checkpoint in immune homeostasis. ICIs targeting CTLA-4, such as ipilimumab, aim to unleash T cell responses by blocking this inhibitory signal, potentially preventing the autoimmune destruction of beta cells in T1D.[10]

The programmed cell death protein 1 (PD-1) receptor and its ligand PD-L1 play a pivotal role in regulating T cell activity.[11] In T1D, aberrant PD-1/PD-L1 interactions contribute to immune tolerance breakdown.[12] Immune checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab inhibit this interaction, allowing for sustained T cell activity. By disrupting this checkpoint, ICIs may prevent the suppression of autoreactive T cells, limiting their assault on beta cells. Immune checkpoint inhibitors (ICIs) exert their effects by modulating T-cell responses, either by enhancing

effector T-cell function or by inhibiting regulatory T-cell activity.[13] In the context of T1D, the delicate balance between effector and regulatory T cells is disrupted, leading to autoimmune destruction. Immune checkpoint inhibitors (ICIs) aim to recalibrate this balance, promoting immune tolerance and mitigating the autoimmune attack on beta cells.

Immune checkpoint inhibitors (ICIs) have the potential to enhance antigen-specific immune responses.[14] In T1D, the identification and targeting of specific autoantigens associated with beta cells can be critical. By unleashing the immune system's specificity, ICIs may redirect T-cell responses towards antigens that promote regulatory mechanisms, thereby attenuating the autoimmune response against beta cells. Beyond the specific targeting of checkpoint molecules, Immune checkpoint inhibitors (ICIs) induce a broader immunomodulatory effect. This includes the activation of various immune cell types, changes in cytokine profiles, and alterations in the tumor microenvironment. In T1D, such immunomodulation may lead to a shift from a pro-inflammatory to an anti-inflammatory state, promoting beta cell survival.[15-16]

Preclinical Studies

Preclinical studies serve as a critical foundation for assessing the efficacy, safety, and mechanisms of action of immune checkpoint inhibitors (ICIs) in the context of Type 1 Diabetes (T1D).[17-18] These investigations, often conducted in murine models of T1D, offer valuable insights into the potential of ICIs for preserving beta cell function and altering the autoimmune trajectory of the disease. Preclinical studies frequently employ murine models, such as non-obese diabetic (NOD) mice, that share immunological and genetic features with human T1D.[19-20] These models allow researchers to recapitulate the autoimmune destruction of beta cells, providing a relevant platform to evaluate the impact of ICIs on disease progression.

Numerous preclinical studies have demonstrated the efficacy of ICIs in preserving beta cell mass and function.[21-22] For example, anti-CTLA-4 antibodies and anti-PD-1/PD-L1 antibodies have shown the ability to attenuate the infiltration of autoreactive T cells into pancreatic islets, reducing the severity of insulitis and maintaining insulin-producing capacity. Preclinical investigations focus on deciphering the specific effects of ICIs on immune responses in T1D.[23-24] These studies often reveal a modulation of T-cell activity, a shift in cytokine profiles, and changes in the balance between effector and regulatory T cells. The goal is to establish a more tolerogenic immune environment that protects beta cells from autoimmune attack.

Markers of autoimmune activity, such as autoantibodies and cytokine levels, are carefully assessed in preclinical studies.[25-26] Changes in these biomarkers provide insights into the direct impact of ICIs on the autoimmune processes associated with T1D, helping to identify potential surrogate markers for treatment response. Preclinical studies contribute to determining optimal dosages of ICIs and assessing their safety profiles. Understanding the dose-response relationship is crucial for translating preclinical findings to clinical settings. Additionally, these studies help identify potential adverse effects and inform strategies for minimizing off-target effects. Exploration of combination therapies is a key aspect of preclinical research. Combinations of ICIs with other

immunomodulatory agents or standard T1D treatments are investigated to enhance therapeutic efficacy while minimizing potential side effects.[27-28] The synergistic effects of such combinations are evaluated in preclinical models. The insights gained from preclinical studies guide the design of clinical trials and inform translational approaches. These studies are instrumental in shaping the rationale for moving ICIs from bench to bedside, providing a basis for further investigations in human subjects.

Clinical Trials

Clinical trials represent a crucial phase in the translation of immune checkpoint inhibitors (ICIs) from preclinical promise to tangible therapeutic interventions for Type 1 Diabetes (T1D) patients. These trials aim to evaluate the safety, efficacy, and tolerability of ICIs in a human population, providing essential insights into their potential as disease-modifying agents. Clinical trials assessing ICIs in T1D carefully design protocols to investigate specific objectives. Patient selection criteria consider factors such as disease duration, age, and baseline insulin requirements. Additionally, inclusion criteria often involve assessing autoantibody status to identify individuals at different stages of autoimmune progression.[29-30] Clinical trials establish primary and secondary endpoints to measure the therapeutic impact of ICIs.[31-32] Primary endpoints may include preservation of beta cell function, reduction in insulin requirements, or improvement in glycemic control. Secondary endpoints often encompass immunological markers, quality of life measures, and safety assessments.

Several clinical trials have investigated the efficacy of anti-CTLA-4 antibodies (e.g., ipilimumab) and anti-PD-1/PD-L1 antibodies (e.g., pembrolizumab, nivolumab) in T1D.[33-34] These trials explore the ability of ICIs to modulate autoimmune responses, with a particular focus on preserving beta cell function and reducing the need for exogenous insulin. Clinical trials involve longitudinal assessments to capture the dynamic changes in disease progression and treatment response. Regular monitoring of glycemic parameters, autoimmune biomarkers, and safety profiles over an extended period allows for a comprehensive evaluation of the sustained effects of ICIs. Advancements in precision medicine are reflected in clinical trials, where efforts are made to identify biomarkers predictive of treatment response.[35-36] Stratifying patients based on their immunological profiles or genetic predispositions enables a more personalized approach, optimizing the likelihood of positive outcomes.

Clinical trials meticulously monitor and report safety data associated with ICIs. Adverse events, including immune-related adverse events (irAEs), are systematically documented to assess the risk-benefit profile. This information guides clinicians in managing potential side effects and informs future trial designs.[37-38] Clinical trials typically progress through different phases. Phase I trials establish safety and dosing, Phase II trials assess efficacy and optimal dosages, and Phase III trials involve larger populations to confirm efficacy and monitor long-term safety. The progression from phase to phase is contingent on positive results and a favorable risk-benefit ratio. Building on insights from preclinical studies, clinical trials explore combination therapies involving ICIs

and other immunomodulatory agents.[39] This approach aims to enhance therapeutic outcomes by targeting multiple facets of the autoimmune response.

Challenges and Considerations

The exploration of immune checkpoint inhibitors (ICIs) as a therapeutic strategy for Type 1 Diabetes (T1D) is met with several challenges and considerations. While promising, these challenges need to be carefully addressed to ensure the safety, efficacy, and feasibility of ICI-based therapies in the complex landscape of autoimmune diabetes. Type 1 Diabetes (T1D) is a heterogeneous disease with variability in disease onset, progression, and underlying immunopathology.[40] Patient heterogeneity poses a challenge in identifying a uniform response to ICIs. Tailoring therapies to individualized immune profiles and disease stages is crucial for optimizing treatment outcomes. Immune checkpoint inhibitors (ICIs) have demonstrated success in cancer immunotherapy but are associated with immune-related adverse events (irAEs).[41] The long-term safety of these agents in the context of T1D, especially considering the chronic nature of the disease, raises concerns. Continuous monitoring for potential side effects and the development of strategies to mitigate irAEs are essential.

Determining the optimal timing for ICI intervention is challenging. Type 1 Diabetes (T1D) is often diagnosed after significant beta cell loss has occurred.[42] Early intervention may be more effective in preserving beta cell function, but the identification of at-risk individuals before clinical onset presents a considerable challenge. Immune checkpoint inhibitors (ICIs) aim to modulate immune responses, but achieving a delicate balance between suppressing autoimmune attacks and maintaining protective immunity is challenging.[43] Indiscriminate immune activation may lead to unintended consequences, including off-target effects and the risk of exacerbating autoimmunity. The identification of reliable biomarkers predictive of treatment response remains a significant challenge. Establishing biomarkers that correlate with disease progression, treatment efficacy, and potential side effects is crucial for patient stratification and personalized medicine approaches.

Developing individualized treatment strategies based on the unique immunological profiles of T1D patients is a complex task.[44] Factors such as age, genetic predisposition, and the presence of specific autoantibodies may influence treatment response, necessitating a personalized medicine approach. While combination therapies hold promise, understanding the synergistic effects and potential synergistic toxicities of combining ICIs with other agents is challenging. Identifying the right combination partners and optimizing dosages require careful consideration to maximize therapeutic benefits. Patient adherence to treatment regimens, especially if involving repeated administrations of ICIs, is critical for therapeutic success.[45] Additionally, patient acceptance of potential risks and benefits, as well as their understanding of the chronic nature of T1D, is essential for the successful implementation of ICI-based therapies.

Future Directions

The exploration of immune checkpoint inhibitors (ICIs) in Type 1 Diabetes (T1D) therapy has opened new avenues for disease modification. As research progresses, several future directions emerge, presenting opportunities to enhance the efficacy, safety, and applicability of ICI-based approaches. Advancements in precision medicine hold the key to tailoring ICI therapies to the unique immunological profiles of T1D patients.[46] Identifying specific biomarkers predictive of treatment response and disease progression will enable more targeted and personalized interventions. Efforts to intervene at earlier stages of T1D, potentially in at-risk individuals before clinical onset, could enhance the efficacy of ICI therapies.[47] Developing reliable markers for early disease detection and establishing the feasibility of preventive interventions are crucial future directions. Exploring synergistic combinations of ICIs with other immunomodulatory agents or standard T1D treatments is a promising avenue.[48] Identifying complementary mechanisms of action and optimizing dosages will be essential for maximizing therapeutic benefits while minimizing potential side effects.

Continued research into the development of next-generation checkpoint inhibitors with improved specificity and reduced off-target effects is crucial. Engineering molecules that selectively modulate autoimmune responses without compromising protective immunity is a key focus for future drug development. Dedicated efforts to discover and validate robust biomarkers for T1D progression and treatment response are imperative.[49] These biomarkers will not only aid in patient stratification but also serve as critical tools for monitoring disease activity and treatment efficacy. T1D often manifests in childhood, and considering the unique immunological aspects of pediatric populations is essential.[50] Future research should focus on understanding the dynamics of immune responses in pediatric T1D and optimizing ICI therapies for this specific demographic. Continued exploration of the mechanistic aspects of ICIs in the context of T1D is essential. Unraveling the intricacies of how these agents modulate immune responses, influence regulatory T cells, and impact the autoimmune milieu will provide valuable insights for refining therapeutic strategies.

Adapting regulatory frameworks to accommodate the unique considerations of autoimmune diseases, including T1D, is critical.[51] Future directions involve engaging regulatory agencies to streamline approval processes and address the specific challenges associated with ICI-based therapies for T1D. Incorporating patient-reported outcomes in clinical trials and real-world settings is crucial for understanding the holistic impact of ICI therapies on the lives of individuals with T1D.[52-54] This includes assessing quality of life, treatment satisfaction, and the psychological aspects of managing a chronic autoimmune condition. Encouraging global collaborations and data-sharing initiatives will facilitate a more comprehensive understanding of the diverse genetic and environmental factors influencing T1D.[55] Large-scale collaborative efforts can accelerate progress and enhance the generalizability of research findings.

Implications for Clinical and Health Policy Making

The exploration of immune checkpoint inhibitors (ICIs) in Type 1 Diabetes (T1D) represents a potential paradigm shift in therapeutic approaches. Clinically, this necessitates a shift from primarily insulin-focused management to immune-modulating strategies aimed at disease

modification. Health policies should encourage and support the integration of precision medicine approaches into clinical practice. Identifying specific biomarkers predictive of treatment response will enable tailored, patient-specific interventions, optimizing the use of ICIs in T1D. Clinical guidelines and policies should be updated to consider and endorse early intervention strategies, aiming to preserve beta cell function and prevent disease progression. This may involve screening programs for at-risk individuals and the inclusion of early intervention protocols in standard care. As evidence accumulates, health policies should consider incorporating ICIs into T1D treatment guidelines. Clear recommendations on the use of ICIs, including patient selection criteria and optimal timing of intervention, will guide clinicians in implementing these novel therapies.[56-67]

Health policies should establish robust safety monitoring protocols for ICI-based therapies in T1D. Clear guidelines for the identification, management, and reporting of immune-related adverse events (irAEs) will ensure the safe implementation of these therapies in clinical settings. Regulatory bodies should adapt existing frameworks to accommodate the unique considerations of autoimmune diseases, specifically T1D. Streamlining approval processes for ICIs in T1D and addressing regulatory challenges will facilitate timely access to these innovative therapies. Health policies should conduct cost-effectiveness assessments of ICI-based therapies for T1D. These assessments will inform reimbursement decisions, ensuring that these novel treatments are economically viable and accessible to a broad patient population. Health policies should support education and training programs for healthcare professionals to enhance their understanding of the immunological basis of T1D and the potential role of ICIs. This ensures that clinicians are well-equipped to integrate these therapies into their practice. Policies should address issues of patient access and equity to prevent disparities in the adoption of ICI-based therapies. This may involve considering reimbursement policies, ensuring affordability, and promoting inclusive participation in clinical trials.[68-87]

Health policies should support public awareness campaigns to inform individuals with T1D, their families, and the broader community about the potential of ICIs. Educating the public will foster informed decision-making and reduce stigma associated with novel therapies. Health policies should encourage international collaboration to facilitate data-sharing initiatives, harmonize regulatory standards, and promote global research efforts. Collaborative endeavors enhance the robustness and generalizability of findings, benefiting the global T1D community. Given the rapid pace of scientific advancements, health policies should adopt adaptive frameworks that can respond to emerging evidence. This flexibility ensures that policies remain dynamic, accommodating new knowledge and innovations in the field of T1D management.[88-94]

Recommendations

Foster collaborations among immunologists, endocrinologists, geneticists, and other specialists to leverage diverse expertise in advancing research and clinical applications of immune checkpoint inhibitors (ICIs) for Type 1 Diabetes (T1D). Invest in precision medicine initiatives to identify and validate biomarkers that can guide patient stratification, predict treatment responses, and support the development of personalized ICI-based therapeutic strategies. Prioritize research focused on

understanding the unique immunological aspects of pediatric-onset T1D and tailor ICI therapies to address the specific needs and challenges of younger populations. Design and conduct clinical trials that explore the feasibility and efficacy of early intervention strategies, aiming to preserve beta cell function and prevent the progression of T1D in at-risk individuals before clinical onset.

Support longitudinal studies to assess the long-term safety and efficacy of ICI-based therapies in T1D, capturing the dynamic nature of autoimmune responses and treatment effects over extended periods. Invest in the research and development of next-generation ICIs with improved specificity, reduced off-target effects, and enhanced efficacy. This includes exploring novel molecular targets and engineering approaches. Encourage research into synergistic combination therapies involving ICIs and other immunomodulatory agents or standard T1D treatments. Optimize dosages and assess the potential for enhanced therapeutic benefits while minimizing adverse effects. Integrate patient-reported outcomes into clinical trials and real-world studies to capture the holistic impact of ICI therapies on individuals with T1D. Assess quality of life, treatment satisfaction, and psychological well-being to inform patient-centered care.

Engage with regulatory bodies to adapt frameworks for autoimmune diseases, facilitating the efficient and safe approval of ICI-based therapies for T1D. Advocate for tailored regulatory approaches that consider the unique characteristics of autoimmune conditions. Promote global collaboration and data-sharing initiatives to create a comprehensive understanding of the genetic, environmental, and immunological factors influencing T1D. Large-scale collaborations can accelerate progress and enhance the generalizability of research findings. Invest in public awareness and education campaigns to inform individuals with T1D, their families, and healthcare professionals about the potential of ICIs as a novel therapeutic approach. Enhance understanding of the evolving landscape of T1D management. Ensure inclusivity in clinical trial enrollment by considering diverse demographics, including different age groups, ethnicities, and disease stages. This inclusivity enhances the generalizability of trial results to a broader T1D population.

Conclusion

The exploration of immune checkpoint inhibitors (ICIs) in the context of Type 1 Diabetes (T1D) marks a transformative chapter in the pursuit of disease-modifying therapies. The intricate interplay between the immune system and beta cells has led researchers and clinicians to investigate novel strategies, and ICIs represent a promising frontier in T1D management. As research progresses, the implications for clinical practice and health policy making are profound. The potential for a therapeutic paradigm shift, embracing precision medicine, and redefining early intervention strategies all underscore the transformative impact of ICIs. While challenges exist, from patient heterogeneity to long-term safety considerations, addressing these hurdles presents opportunities for innovation and progress.

References

1. Obeagu EI, Obeagu GU. Type 1 diabetes mellitus: Roles of neutrophils in the pathogenesis. Medicine. 2023;102(50): e36245.

Citation: Obeagu EI, Obeagu GU. Immune Checkpoint Inhibitors in Type 1 Diabetes: A New Frontier in Therapy. Elite Journal of Medicine, 2024; 2(2): 26-41

2. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
3. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(4):110-7.
4. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. Int. J. Adv. Multidiscip. Res. 2016;3(3):9-14.
5. Kiaie SH, Salehi-Shadkami H, Sanaei MJ, Azizi M, Shokrollahi Barough M, Nasr MS, Sheibani M. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. Journal of nanobiotechnology. 2023;21(1):339.
6. Janež A, Guja C, Mitrakou A, Lalic N, Tankova T, Czupryniak L, Tabák AG, Prazny M, Martinka E, Smircic-Duvnjak L. Insulin therapy in adults with type 1 diabetes mellitus: a narrative review. Diabetes Therapy. 2020:387-409.
7. Shiravand Y, Khodadadi F, Kashani SM, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Current Oncology. 2022;29(5):3044-3060.
8. Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug discovery today. 2020;25(1):223-9.
9. Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury Junior JR. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Human Cell. 2023:1-8.
10. Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory properties of immune checkpoint inhibitors—more than boosting T-cell responses? Cancers. 2022;14(7):1710.
11. Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacology & Therapeutics. 2019; 194:84-106.
12. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences. 2011;1217(1):45-59.
13. Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell International. 2023;23(1):64.
14. Lee J, Kim EH. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy. Frontiers in Oncology. 2023;13.
15. Varayathu H, Sarathy V, Thomas BE, Mufti SS, Naik R. Combination strategies to augment immune check point inhibitors efficacy-implications for translational research. Frontiers in oncology. 2021; 11:559161.
16. Simpson RC, Shanahan ER, Scolyer RA, Long GV. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology. 2023;20(10):697-715.

Citation: Obeagu EI, Obeagu GU. Immune Checkpoint Inhibitors in Type 1 Diabetes: A New Frontier in Therapy. Elite Journal of Medicine, 2024; 2(2): 26-41

17. Cantley J, Eizirik DL, Latres E, Dayan CM. Islet cells in human type 1 diabetes: from recent advances to novel therapies–a symposium-based roadmap for future research. Journal of Endocrinology. 2023;259(1).
18. Gacche RN. Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2023:189020.
19. Pearson JA, Wong FS, Wen L. The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. Journal of autoimmunity. 2016; 66:76-88.
20. Funda DP, Palová-Jelínková L, Goliáš J, Kroulíková Z, Fajstová A, Hudcovic T, Špíšek R. Optimal tolerogenic dendritic cells in type 1 diabetes (T1D) therapy: what can we learn from non-obese diabetic (NOD) mouse models? Frontiers in Immunology. 2019; 10:967.
21. Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nature reviews Clinical oncology. 2022;19(12):775-90.
22. Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome medicine. 2021;13(1):107.
23. Cina ML, Venegas J, Young A. Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events. Immunological Reviews. 2023;318(1):110-37.
24. Calabrese LH. Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy: A Handbook for Diagnosis and Management. 2021:49-68.
25. Ma WT, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. Journal of autoimmunity. 2017; 83:95-112.
26. Kalinkovich A, Gabdulina G, Livshits G. Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis. Immunologic Research. 2018; 66:696-709.
27. Isaacs D, Drakaki A, Xing Y, In G, Angell T, Lechner M, Hilder R, Tsai K, Quandt Z. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
28. Ding JT, Yang KP, Lin KL, Cao YK, Zou F. Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes. Frontiers in Endocrinology. 2023; 13:1090842.
29. Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clinical drug investigation. 2019; 39:319-30.
30. Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. InSeminars in cancer biology 2022; 79:18-43. Academic Press.
31. Reynolds KL, Arora S, Elayavilli RK, Louv WC, Schaller TH, Khandelwal A, Rothenberg M, Khozin S, Guidon AC, Dougan M, Zubiri L. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. Journal for ImmunoTherapy of Cancer. 2021;9(7).

32. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annual Review of Pathology: Mechanisms of Disease. 2021; 16:223-249.
33. Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews. 2021; 40:949-982.
34. Wong SK, Beckermann KE, Johnson DB, Das S. Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and-programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opinion on Biological Therapy. 2021;21(12):1623-1634.
35. Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? Journal of translational medicine. 2019; 17:1-28.
36. Tarhini A, Kudchadkar RR. Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer treatment reviews. 2018; 71:8-18.
37. Rzeniewicz K, Larkin J, Menzies AM, Turajlic S. Immunotherapy use outside clinical trial populations: never say never? Annals of Oncology. 2021;32(7):866-880.
38. Pasello G, Pavan A, Attili I, Bortolami A, Bonanno L, Menis J, Conte P, Guarneri V. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. Cancer treatment reviews. 2020; 87:102031.
39. Fulgenzi CA, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opinion on Investigational Drugs. 2022;31(7):681-691.
40. Infante M, Alejandro R, Fabbri A, Ricordi C. The heterogeneity of type 1 diabetes: From immunopathology to immune intervention. InTranslational Autoimmunity 2022: 83-104. Academic Press.
41. Lee DJ, Lee HJ, Farmer JR, Reynolds KL. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Current Cardiology Reports. 2021; 23:1-2.
42. Oram RA, Sims EK, Evans-Molina C. Beta cells in type 1 diabetes: mass and function; sleeping or dead? Diabetologia. 2019; 62:567-77.
43. Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: Focus on tumor immune microenvironment. Annals of Translational Medicine. 2020;8(17).
44. Linsley PS, Greenbaum CJ, Nepom GT. Uncovering pathways to personalized therapies in type 1 diabetes. Diabetes. 2021;70(4):831-41.
45. Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal transduction and targeted therapy. 2020;5(1):146.
46. Deligiorgi MV, Trafalis DT. A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2023;24(8):7630.

47. Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies. Frontiers in pharmacology. 2019; 10:1453.
48. Kiaie SH, Salehi-Shadkami H, Sanaei MJ, Azizi M, Shokrollahi Barough M, Nasr MS, Sheibani M. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. Journal of nanobiotechnology. 2023;21(1):339.
49. Yi L, Swensen AC, Qian WJ. Serum biomarkers for diagnosis and prediction of type 1 diabetes. Translational Research. 2018; 201:13-25.
50. Bauer W, Gyenesei A, Krętowski A. The multifactorial progression from the islet autoimmunity to type 1 diabetes in children. International Journal of Molecular Sciences. 2021;22(14):7493.
51. James EA, Joglekar AV, Linnemann AK, Russ HA, Kent SC. The beta cell-immune cell interface in type 1 diabetes (T1D). Molecular Metabolism. 2023:101809.
52. Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. Journal for immunotherapy of cancer. 2021;9(9).
53. Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Journal for immunotherapy of cancer. 2021;9(8).
54. Gusev A. Germline mechanisms of immunotherapy toxicities in the era of genome-wide association studies. Immunological Reviews. 2023;318(1):138-156.
55. Flannick J, Florez JC. Type 2 diabetes: genetic data sharing to advance complex disease research. Nature Reviews Genetics. 2016;17(9):535-549.
56. Gacche RN. Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2023:189020.
57. Pritchard DE, Moeckel F, Villa MS, Housman LT, McCarty CA, McLeod HL. Strategies for integrating personalized medicine into healthcare practice. Personalized medicine. 2017;14(2):141-52.
58. Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, Dendale P, Doherty P, Gaita D, Höfer S, McGee H. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. European journal of preventive cardiology. 2014;21(6):664-81.
59. Richardson SJ, Pugliese A. 100 YEARS OF INSULIN: Pancreas pathology in type 1 diabetes: an evolving story. Journal of endocrinology. 2022;252(2): R41-57.
60. Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nature Reviews Endocrinology. 2021;17(7):389-99.
61. Ross ER, Altimus C. Type 1 Diabetes Autoantibody Screening: A Roadmap for Pediatric Policy Implementation. Milken Institute. 2021.

Citation: Obeagu EI, Obeagu GU. Immune Checkpoint Inhibitors in Type 1 Diabetes: A New Frontier in Therapy. Elite Journal of Medicine, 2024; 2(2): 26-41

62. Von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE. Immunotherapy use in patients with lung cancer and comorbidities. Cancer journal (Sudbury, Mass.). 2020;26(6):525.
63. Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW. Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced malignant melanoma. JAMA Network Open. 2022;5(12):e2246400-.
64. Mountzios G, Remon J, Hendriks LE, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC. Immune-checkpoint inhibition for resectable non-small-cell lung cancer—Opportunities and challenges. Nature Reviews Clinical Oncology. 2023;20(10):664-77.
65. Hedman Ahlström B. Focus on Every-day Life: Internet-based Support and Coaching for Young Adults with Neuropsychiatric Disorders-A Chat-log Analysis. InIV. World Congress on Social Media and Web 2.0 in Medicine, Health and Biomedical research. Medicine 2.0 at Stanford university 2011: 27-28.
66. Núñez-Baila MÁ, Gómez-Aragón A, Marques-Silva AM, González-López JR. Lifestyle in Emerging Adults with Type 1 Diabetes Mellitus: A Qualitative Systematic Review. InHealthcare 2024; 12(3):309. MDPI.
67. Phiri T, Mowat R, Cook C. What nursing interventions and healthcare practices facilitate type 1 diabetes self-management in young adults? An integrative review. Nursing Praxis in Aotearoa New Zealand. 2022;38(2):32-43.
68. Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP. Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov. 2016;5(1):68-82. links/5ae45fdfaca272ba507eb3c3/PREVALENCE-OF-URINARY-TRACT-INFECTION-IN-DIABETIC-PATIENTS-ATTENDING-UMUAHIA-HEALTH-CARE-FACILITIES.pdf.
69. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(2):rqad010.
70. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. J Diabetes Clin Prac. 2018;1(102):2. links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf.
71. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(4):110-7. links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo-state-Nigeria.pdf.
72. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. Evaluation of some trace elements in streptozocin induced diabetic rats treated with Moringa oleifera leaf powder. WJPMR. 2020;6(12):15-8. links/5fcb587092851c00f8516430/EVALUATION-OF-SOME-

TRACE-ELEMENTS-IN-STREPTOZOCIN-INDUCED-DIABETIC-RATS-TREATED-WITH-MORINGA-OLEIFERA-LEAF-POWDER.pdf.

73. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-121.
74. Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in Mnazi Mmoja Hospital, Zanzibar. Journal of Pharmaceutical Research International. 2021;33(29B):67-78.
75. Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF. Effect of Extracts of Kigelia Africana Fruit and Sorghum Bicolor Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. Journal of Pharmaceutical Research International. 2021;33(25B):86-97.
76. Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeme M, Ukeekwe CO, Amaeze AA. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. Journal of Pharmaceutical Research International. 2020 Nov 17;32(28):117-121.
77. Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI. Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. Journal of Pharmaceutical Research International. 2021:40-45.
78. Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT, Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringa oleifera Leaf. Journal of Pharmaceutical Research International. 2021;33(28A):78-86.
79. Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE. Evaluation of Lipoprotein A and Lipid Tetrad Index Pattern in Diabetic Patients Attending Metabolic Clinic in The Federal Medical Centre, Owerri, Imo State. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):126-140
80. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. Asian Journal of Dental and Health Sciences. 2023 Jun 15;3(2):32-36. http://ajdhs.com/index.php/journal/article/view/43.
81. Adu ME, Chukwuani U, Ezeoru V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU. Studies on molecular docking of moringa oleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. Journal of Pharmaceutical Research International. 2021;33(28A):239-345.
82. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic

Individuals at NAUTH, Nnewi, Nigeria. Journal of Pharmaceutical Research International. 2021;33(47B):242-248.
83. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-206.
84. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
85. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. Int. J. Adv. Multidiscip. Res. 2016;3(3):9-14.
86. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. European Journal of Biomedical. 2020;7(11):285-288.
87. Nwosu DC, Nwanjo HU, Opara AU, Ofor IB, Obeagu EI, Ugwu GU, Ojiegbe GC, Nnorom RM, Nwokike GI, Okpara KE, Ochei KC. EVALUATION OF C-REACTIVE PROTEIN, SELENIUM AND GLYCOSYLATED HAEMOGLOBIN LEVELS IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. **World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):141-152.** https://www.academia.edu/download/38320132/NWOSU_EMMA_9.pdf.
88. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF KIDNEY INJURY MOLECULE-1, CYSTATIN C, AND SERUM ELECTROLYTES IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. Education. 2002.
89. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and gas chromatography-mass spectrometry (GC-MS) analysis of ethanol root extract and fractions of Sphenocentrum jollyanum. RPS Pharmacy and Pharmacology Reports. 2023;2(2): rqad007.
90. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023;11(1):25-30.
91. Ugwu OP, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AO, Amusa MO, Adepoju AO. Effect of Ethanol leaf extract of Chromolaena odorata on lipid profile of streptozotocin induced diabetic wistar albino rats. IAA Journal of Biological Sciences. 2023;10(1):109-117.
92. Ifeanyi OE. Gestational Diabetes: Haematological Perspective. **South Asian Research Journal of Applied Medical Sciences, 1 (2):41-42. DOI: 10.36346/SARJAMS.2019.v01i02.003** https://sarpublication.com/media/articles/SARJAMS_12_41-42.pdf.
93. Ogbu IS, Odeh EJ, Ifeanyichukwu OE, Ogbu C, Ude UA, Obeagu EI. Prevalence of prediabetes among first degree relatives of type 2 diabetes individuals in Abakaliki, Ebonyi

State Nigeria. Academic Journal of Health Sciences: Medicina Balear. 2023;38(2):85-88. https://dialnet.unirioja.es/servlet/articulo?codigo=8845439.

94. Ifeanyi OE. An update on Diabetes Mellitus. Int. J. Curr. Res. Med. Sci. 2018;4(6):71-81.DOI: 10.22192/ijcrms.2018.04.06.012 links/5b3b97a04585150d23f63e76/An-update-on-Diabetes-Mellitus.pdf.